Glioblastoma multiforme in an Asian population: Evidence for a distinct genetic pathway

Journal of Neuro-Oncology

Volumn 60, Issue 2, 2002, Pages 117-125

  Das, A ^a   Tan, W L ^a   Teo, J ^a   Smith, D R ^b  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

EGFR; mdm2; p53; PDGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; CANCER CLASSIFICATION; CANCER GENETICS; CANCER MODEL; CARCINOGENESIS; CHILD; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; POPULATION RESEARCH; SAMPLE; SEQUENCE ANALYSIS; SINGAPORE;

ADULT; AGED; BRAIN NEOPLASMS; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036843770     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020622415786     Document Type: Article

References (31)

1. Zulch KJ: Brain Tumors. Their Biology and Pathology. 3rd edn., Springer Verlag, Berlin Heidelberg, 1986
2. Das A, Chapman CAT, Yap WM: Histological subtypes of symptomatic central nervous system tumours in Singapore. J Neurol Neurosurg Psych 68: 370-374, 2000
3. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223, 1996
4. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997
5. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684-689, 1998
6. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 94: 303-309, 1997
7. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK: Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and Genetics of Tumors of the Nervous System. International Agency for Research on Cancer, Lyon, 1997, pp 16-24
8. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncol 1: 44-51, 1999
9. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immnoperoxidase techniques. J Histochem Cytochem 29: 577-580, 1981
10. Lau KE: Singapore census of population 1990. Statistical Release 1: Demographics and Characteristics. Department of Statistics, Singapore 1992
11. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24: 141-146, 1996
12. Beroud C, Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 26: 200-204, 1998
13. Ohgaki H, Schäuble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 427: 113-118, 1995
14. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 513-530, 1997
15. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313: 144-147, 1985
16. Ekstrand AJ, Sugawa N, James CD, Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309-4313, 1992
17. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969, 1992
18. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplitication and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997
19. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodeman HP, Bamberg M: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neuro-Oncol 49: 197-203, 2000
20. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A, Nister M: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor receptor expression in human malignant gliomas. Cancer Res 56: 164-171, 1996
21. Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26: 1-5, 1994
22. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994
23. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235, 1993
24. von Deimling A, von Ammon K, Schoenfeld DA, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993
25. Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M: Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 61: 3949-3954, 2001
26. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JCS, Lo KW: Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58: 120-128, 1999
27. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AS, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993
28. Elledge RM, Clark GM, Chamness GC, Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712, 1994
29. Shiao YH, Chen VW, Wu XC, Scheer WD, Lehmann HP, Malcom GT, Boudreau DA, Ruiz B, Correa P: Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo 10: 169-173, 1996
30. Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith DR: Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer 83: 761-768, 2000
31. Watanabe M, Fukutome K, Shiraishi T, Murata M, Kawamura J, Shimazaki J, Kotake Y, Yatani R: Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 18: 1355-1358, 1997